Please use this identifier to cite or link to this item:
https://doi.org/10.1080/02841860600702076
DC Field | Value | |
---|---|---|
dc.title | Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma | |
dc.contributor.author | Chuah, B. | |
dc.contributor.author | Lim, R. | |
dc.contributor.author | Boyer, M. | |
dc.contributor.author | Ong, A.-B. | |
dc.contributor.author | Wong, S.-W. | |
dc.contributor.author | Kong, H.-L. | |
dc.contributor.author | Millward, M. | |
dc.contributor.author | Clarke, S. | |
dc.contributor.author | Goh, B.-C. | |
dc.date.accessioned | 2016-11-29T01:19:41Z | |
dc.date.available | 2016-11-29T01:19:41Z | |
dc.date.issued | 2007 | |
dc.identifier.citation | Chuah, B., Lim, R., Boyer, M., Ong, A.-B., Wong, S.-W., Kong, H.-L., Millward, M., Clarke, S., Goh, B.-C. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica 46 (2) : 234-238. ScholarBank@NUS Repository. https://doi.org/10.1080/02841860600702076 | |
dc.identifier.issn | 0284186X | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/131526 | |
dc.description.abstract | Hepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma. The purpose of this multi-centre phase II study was to evaluate the efficacy and toxicity of thalidomide in patients with advanced HCC. From February 2000 to November 2001, 37 patients with histologically proven, bi-dimensionally measurable advanced, unresectable HCC were enrolled. The starting dose of Thalidomide was 100 mg per day and escalated weekly by 100 mg to a maximum dose of 800 mg/day according to individual patient tolerance. Radiological tumour response and treatment related toxicities were prospectively assessed. Thirty-seven patients were evaluable for toxicity and 24 patients were evaluable for response. The median Thalidomide dose was 400 mg/day. There was no complete response (CR). One patient had a radiological partial response (PR) (3%; 95% confidence interval [95% CI], 0% to 8%) and six (16%) patients had stable disease for more than 6 months. Somnolence and fatigue were the most common side effects, occurring in 84% and 73% of patients respectively. Thalidomide monotherapy is tolerable and associated with modest antitumour activity in advanced HCC. © 2007 Taylor & Francis. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1080/02841860600702076 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.1080/02841860600702076 | |
dc.description.sourcetitle | Acta Oncologica | |
dc.description.volume | 46 | |
dc.description.issue | 2 | |
dc.description.page | 234-238 | |
dc.description.coden | ACTOE | |
dc.identifier.isiut | 000244522200015 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.